Philips and Ypsomed said today that they will jointly develop a solution for Ypsomed’s new self-medication adherence monitoring services based on Philips’ HealthSuite digital platform.

The combination of Ypsomed’s connected devices and Philips’ (NYSE:PHG) cloud-based digital platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services aimed at improving patient outcomes, the companies said in a joint statement. They intend to sign the definitive agreements in the fourth quarter of 2018.

Ypsomed describes its SmartServices as a new turnkey digital solution for medication adherence monitoring and smart device management. Philips’ HealthSuite digital platform provides tools and services focused on ease-of-integration, digital lifecycle management, and end-to-end security, according to that company.

Ypsomed makes injections pens, autoinjectors and infusion systems to administer liquid drugs. The new digital services aim to address a wide range of device-oriented challenges and support self-medication services for patients across chronic disease states, such as diabetes, multiple sclerosis, and rheumatoid arthritis.

“Our partnership with Philips aims at embedding smart devices in a digital health ecosystem that simplifies access to therapy-relevant medication adherence data,” said Ulrike Bauer, senior vice president of Ypsomed Delivery Systems, in the statement. “This will allow our pharmaceutical customers to focus on building therapy-specific digital solutions for patients, caregivers, and physicians.”

Integrating Ypsomed’s smart devices and data into HealthSuite will enable pharma companies to achieve shorter time-to-market, scale-up solutions in a secure HIPAA-compliant way, and integrate data from Ypsomed devices with other data sources to support other value-added use cases, said Philips’ HealthSuite business leaderDale Wiggins.